Objective   This work aims to determine the efficacy of intraoperative chemohyperthermic peritoneal perfusion (ICHPP) on the prognosis of patients with advanced gastric cancer of different stages.

  Methods   Ninety patients were divided into the treatment (Group A) and control groups (Group B), all of which underwent radical gastrectomy and D2 node dissection. The patients in Group A received ICHPP therapy after surgery, whereas those in Group B underwent a gastric carcinoma resection without ICHPP. Chemotherapy using a FOLFOX4 regimen, particularly, oxaliplatin, fluorouracil, and calcium leucovorin, was administered intravenously in both groups, four weeks after surgery. Systemic chemotherapy was administered for 12 cycles. Hepatorenal functions were determined in the patients with advanced gastric cancer before and after the surgery. The survival rates in both groups were observed and compared.

  Results   Peripheral blood albumin levels significantly decreased in Group A, 7 days after the treatment (32.34 g/L ± 2.23 g/L, 46.45 g/L ± 4.81 g/L; P < 0.05 vs. pre-operation), but were significantly lower compared with Group B (32.34 g/L ± 2.23 g/L, 41.45 g/L ± 5.25 g/L, P < 0.05 vs. Group B). For the stage ⅡB cases, the 5-year survival rate was 66.7% in Group A and 60% in Group B. No significant differences were observed between the two groups (P> 0.05). For the stage ⅢA cases, the 5-year survival rate was 63.6% in Group A and 58.3% in Group B. No significant differences were observed between the two groups (P>0.05). For the stage ⅢB cases, the 5-year survival rate was 40.9% in Group A and 27.3% in Group B. The differences between the two groups were significant (P < .05). For the stage-IIIC cases, the 5-year survival rate was 28.6% in Group A and 20% in Group B, without significant differences between the two groups (P>0.05).

  Conclusion  Surgical resection combined with HIPEC may prolong survival of the patients with stage Ⅲb gastric carcinoma.